Page 59 - Read Online

Page 10 of 10 Puppala. Hepatoma Res 2019;5:44 I http://dx.doi.org/10.20517/2394-5079.2019.28

following transarterial chemoembolisation (TACE) in patients with hepatocellular carcinoma (HCC). Eur Radiol 2014;24:1105-11.
20. Aoe M, Kanemitsu T, Ohki T, Kishi S, Ogura Y, et al. Incidence and risk factors of contrast-induced nephropathy after transcatheter
arterial chemoembolization in hepatocellular carcinoma. Clin Exp Nephrol 2019;23:1141-6.
21. Sun W, Xu F, Li X, Li CR. Case series of liver abscess formation after transcatheter arterial chemoembolization for hepatic tumors.
Chin Med J (Engl) 2017;130:1314-9.
22. Fohlen A, Tasu JP, Kobeiter H, Bartoli JM, Pelage JP, et al. Transarterial chemoembolization (TACE) in the management of
hepatocellular carcinoma: results of a French national survey on current practices. Diagn Interv Imaging 2018;99:527-35.
23. Seki A, Hori S, Kobayashi K, Narumiya S. Transcatheter arterial chemoembolization with epirubicin-loaded superabsorbent polymer
microspheres for 135 hepatocellular carcinoma patients: single-center experience. Cardiovasc Intervent Radiol 2011;34:557-65.
24. Gomes AS, Monteleone PA, Sayre JW, Finn RS, Sadeghi S, et al. Comparison of triple-drug transcatheter arterial chemoembolization
(TACE) with single-drug TACE using doxorubicin-eluting beads: long-term survival in 313 patients. AJR Am J Roentgenol
2017;209:722-32.
25. Aliberti C, Carandina R, Lonardi S, Dadduzio V, Vitale A, et al. Transarterial chemoembolization with small drug-eluting beads
in patients with hepatocellular carcinoma: experience from a cohort of 421 patients at an Italian Center. J Vasc Interv Radiol
2017;28:1495-502.
26. Richter G, Radeleff B, Stroszczynski C, Pereira P, Helmberger T, et al. Safety and feasibility of chemoembolization with doxorubicin-
loaded small calibrated microspheres in patients with hepatocellular carcinoma: results of the MIRACLE I prospective multicenter
study. Cardiovasc Intervent Radiol 2018;41:587-93.
27. Burrel M, Reig M, Forner A, Barrufet M, de Lope CR, et al. Survival of patients with hepatocellular carcinoma treated by transarterial
chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol 2012;56:1330-5.
28. Malagari K, Moschouris H, Kiakidis T, Harward S, Kelekis A, et al. Five-years outcome analysis of 142 consecutive hepatocellular
carcinoma patients treated with doxorubicin eluting microspheres 30-60 μm: results from a single-centre prospective phase ii trial.
Cardiovasc Intervent Radiol 2019;42:1551-62.
29. Malagari K, Pomoni A, Filippiadis D, Kelekis D. Chemoembolization of hepatocellular carcinoma with HepaSphere™. Hepat Oncol
2015;2:147-57.
30. Gjoreski A, Popova-Jovanovska R, Eftimovska-Rogac I, Vejseli J. Safety profile and efficacy of chemoembolization with doxorubicin
- loaded polyethylene glycol microspheres in patients with hepatocellular carcinoma. Open Access Maced J Med Sci 2019;7:742-6.
31. Reicher J, Mafeld S, Priona G, Reeves HL, Manas DM, et al. Early experience of trans-arterial chemo-embolisation for hepatocellular
carcinoma with a novel radiopaque bead. Cardiovasc Intervent Radiol 2019;42:1563-70.
32. Orlacchio A, Chegai F, Francioso S, Merolla S, Monti S, et al. Repeated transarterial chemoembolization with degradable starch
microspheres (DSMs-TACE) of unresectable hepatocellular carcinoma: a prospective pilot study. Curr Med Imaging Rev 2018;14:637-
45.
33. Orlacchio A, Chegai F, Roma S, Merolla S, Bosa A, et al. Degradable starch microspheres transarterial chemoembolization (DSMs-
TACE) in patients with unresectable hepatocellular carcinoma (HCC): long-term results from a single-center 137-patient cohort
prospective study. Radiol Med 2019; Epub ahead of print [PMID: 31583558 DOI: 10.1007/s11547-019-01093-x]
34. Meng XX, Liao HQ, Liu HC, Jiang HL, Gu YF, et al. Application of side-hole catheter technique for transradial arterial
chemoembolization in patients with hepatocellular carcinoma. Abdom Radiol (NY) 2019;44:3195-9.
35. Hatanaka T, Arai H, Kakizaki S. Balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma. World J
Hepatol 2018;10:485-95.
36. Pung L, Ahmad M, Mueller K, Rosenberg J, Stave C, et al. The role of cone-beam CT in transcatheter arterial chemoembolization
forhepatocellular carcinoma: a systematic review and meta-analysis. J Vasc IntervRadiol 2017;28:334-41.
37. Kim HC. Role of C-arm cone-beam CT in chemoembolization for hepatocellular carcinoma. Korean J Radiol 2015;16:114-24.
38. Loffroy R, Favelier S, Cherblanc V, Estivalet L. C-arm dual-phase cone-beam CT: a revolutionary real-time imaging modality to
assess drug-eluting beads TACE success in liver cancer patients. Quant Imaging Med Surg 2013;3:196-9.
39. Ford J. Transradial approach for interventional oncology: an interview with Darren Klass, MD. Intervent Oncol 360. 2016;4:E55-60.
Available from https://www.iolearning.com/article/transradial-approach-interventional-oncology-interview-darren-klass-md [Last
accessed on 31 Dec 2019]
40. Valgimigli M, Gagnor A, Calabró P, Frigoli E, Leonardi S, et al.; MATRIX Investigators. Radial versus femoral access in patients
with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. Lancet 2015;385:2465-76.
41. Chen O, Goel S, Acholonu M, Kulbak G, Verma S, et al. Comparison of standard catheters versus radial artery-specific catheter in
patients whounderwent coronary angiography through transradial access. Am J Cardiol 2016;118:357-61.
42. Chen YP, Zhang JL, Zou Y, Wu YL. Recent advances on polymeric beads or hydrogels as embolization agents for improved
transcatheter arterial chemoembolization (TACE). Front Chem 2019;7:408.